x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The Readout Loud

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

business

All Episodes

36:40

285: CRISPR history, biotech struggles, & a big week...

The Readout Loud ·

2023/12/07

With the first CRISPR-based medicine expected to win FDA approval any minute now, STAT’s Megan Molteni joins us to discuss how we got here and what it means for the future. Then, Bruce Booth from Atlas Venture joins us to discuss what was yet another downbeat year for biotech and whether there’s reason for optimism heading into 2024. To keep up with biotech news throughout the week, here's where you can subscribe to our newsletter, The Readout.

en

28:39

284: AbbVie’s big deal, CAR-T’s risks, & getting a...

The Readout Loud ·

2023/11/30

We discuss why AbbVie is spending $10 billion on a cancer-focused company that spent four decades on the path to its first FDA approval, a deal with implications for biotech in 2023 and for a burgeoning area in oncology. We’ll also talk about the latest news in the life sciences, including safety concerns for CAR-T cancer treatment, the slumping industry job market, and some curious explanations for clinical failures.

en

30:41

283: A CRISPR milestone, algorithms amok, & biotech...

The Readout Loud ·

2023/11/16

Our colleague Casey Ross joins us to tell the bombshell story of how the nation's largest health insurer used a computer algorithm to deny patient care and boost its profitability. Then, biotech veteran Michael Gilman calls in to offer a behind-the-scenes peek at what it’s like to be a startup CEO in this economic downturn — and which cocktail recipes help make it bearable. We also discuss a pioneering approval for a genome-editing medicine.

en

29:50

From Tradeoffs: Can the U.S. put an end to surprise...

The Readout Loud ·

2023/11/13

From our reporting partners at Tradeoffs: Congress banned most surprise medical bills back in 2020, with one major exception: ambulance rides. Most people agree that patients should be shielded from these unexpected charges. But who should pick up the tab instead? This week, as state and federal policymakers grapple with that question, we delve into why finding a fair solution is harder than you’d think. You can also check out our STAT story for more information. Note: This episode has been

en

37:01

282: Lilly’s obesity drug, the power of radiation, &...

The Readout Loud ·

2023/11/09

As so-called radiopharmaceuticals make headlines in oncology, we explore their fascinating scientific backstory and the biotech gold rush to make them. We also discuss the approval of Eli Lilly’s curiously named treatment for obesity, the latest implosion for a promising biotech company, and some news in the world of shareholder activism. To keep up between podcast episodes, here’s where you can subscribe to our biotech newsletter, The Readout.

en

32:29

281: Decoding biotech hype, the Sarepta saga, & au...

The Readout Loud ·

2023/11/02

Biotech consultant Frank David joins us to explain the wild world of subgroup analyses and how to discern science from spin. We also discuss the latest news in the life sciences, including the future of Sarepta and the retirement of a biotech stalwart. For more on what we cover, here's where you can read Frank's work; here's more on Sarepta; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here's where you can subscribe to our biotech

en

29:48

280: ESMO highlights, Roivant's big deal, & biotech...

The Readout Loud ·

2023/10/26

Our colleague Andrew Joseph joins us to explain the decades-old cancer-treating technology that had its star turn at this week's big oncology conference in Europe. We also discuss the latest news in the life sciences, including the future of Alzheimer’s disease treatment, a multibillion-dollar deal, and the return of the biotech mega-round. For more on what we cover, here's STAT's coverage of the European Society for Medical Oncology meeting; here's more on Roivant Sciences; here's the latest on

en

33:14

279: Live from the 2023 STAT Summit

The Readout Loud ·

2023/10/19

Live from Boston at the 2023 STAT Summit, we discuss the latest news in the life sciences, including a milestone in genome editing, a twist in the search for ALS treatments, and the polarizing process of saying words in biotech.

en

32:57

278: Merger Mondays, Ozempic panic, & CRISPR'd pigs

The Readout Loud ·

2023/10/12

We discuss Bristol Myers Squibb’s multibillion-dollar acquisition of Mirati Therapeutics and what it means for a biotech sector still in a slump. We also explain the latest news in the life sciences, including Wall Street’s freakout over GLP-1, CRISPR’ing animals, and the latest in the NASH saga.

en

31:06

277: Is the Nobel committee evolving? Plus,...

The Readout Loud ·

2023/10/05

It’s Nobel week on the podcast, and reporter Megan Molteni details the unique story of this year’s winners for medicine, Katalin Karikó and Drew Weissman. Then, our colleague Jason Mast joins us to explain the scientific and ethical quandaries facing the teams attempting to develop HIV vaccines.

en

34:47

276: Who discovered GLP-1? Plus: BrainStorm at the...

The Readout Loud ·

2023/09/28

Our colleague Elaine Chen joins us to explain the story of Svetlana Mojsov, a chemist who played a vital role in the discovery of GLP-1 who has spent decades fighting for proper recognition. We also discuss the latest news in the life sciences, including the FDA hearing on a BrainStorm Cell Therapeutics' polarizing ALS treatment, the end of the road for a once-vaunted drug developer, and the sorry state of biotech stocks.

en

33:03

275: A thorny ALS debate at the FDA, and the promise...

The Readout Loud ·

2023/09/21

Our colleague Lizzy Lawrence joins us to explain the promise of artificial wombs and the debate over how to ethically develop them. We also discuss a momentous upcoming meeting in which FDA will consider the thorny case of a potential medicine for ALS whose supporting evidence has polarized patients and physicians.

en

39:27

274: Covid’s latest surge, Alnylam at the FDA, & the...

The Readout Loud ·

2023/09/14

Our colleague Helen Branswell joins us to discuss the state of the Covid-19 pandemic heading into the fall and the rollout of boosters shots aimed at the latest viral variants. We also discuss the latest news in the life sciences, including an IPO implosion, a debate at the FDA, and the ups and downs of a career in biotech.

en

33:31

273: Back to school for biotech, Biogen's potential...

The Readout Loud ·

2023/09/07

Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters the busy back third of 2023. We also discuss the latest news in the life sciences, including some scientific evolution at Biogen, new leadership at Illumina, and the future of CRISPR medicine.

en

29:30

272: Vivek's star turn, leaky drug data, & biotech as...

The Readout Loud ·

2023/08/24

We discuss how Vivek Ramaswamy, fresh off his headline-grabbing debut at the first Republican presidential debate, went from a drug industry entrepreneur to a GOP rising star — and how his former biotech colleagues are reacting to it. We also explain the latest news in the life sciences, including a curious data leak and the family business of a famed biotech inventor.

en

34:56

271: Racing for gene therapy, a pioneering approval,...

The Readout Loud ·

2023/08/18

Our colleague Jason Mast joins us to explain how the approval of a landmark gene therapy for Duchenne muscular dystrophy set in motion a frantic race to get children treated before their 6th birthdays. Then, HSBC Managing Director Jonathan Norris calls in to discuss why so many biotech startups are facing financial bridges to nowhere.

en

32:52

270: Your guide to Wegovy’s blockbuster heart study

The Readout Loud ·

2023/08/10

In the wake of a massively important clinical trial of Novo Nordisk’s obesity drug Wegovy, our colleague Elaine Chen joins us to explain what we know and don’t know about data that could change the practice of medicine. Then, Mizuho Securities biotech strategist Jared Holz calls in to discuss whether explosive popularity of obesity treatments could help create the first trillion-dollar drug company.

en

37:27

269: Biotech layoffs, eye drug drama, & gene therapy...

The Readout Loud ·

2023/08/03

First, we discuss how some recent layoffs and a reverse merger mean for biotech in 2023. We’ll also discuss the latest news in the life sciences, including a dramatic saga in ocular medicine, the volatile business of Covid-19, and some major milestones in gene therapy.

en

36:25

268: Biogen's sticky situation, Wegovy's risks, &...

The Readout Loud ·

2023/07/27

First, we discuss why Wall Street was less than convinced by Biogen's attempt to assuage concerns about its credibility. Then we explain an insider trading scandal that bridges biotech and elite-level soccer, the latest concerns over Wegovy, and the rest of the week's news in the life sciences. We also break some bittersweet news, with the help of some headline names from around biotech.

en

35:26

267: BridgeBio's big week, Lilly's Alzheimer's data,...

The Readout Loud ·

2023/07/20

Neil Kumar, CEO of BridgeBio, joins us to talk about how his small company came to develop what could be a big drug — and why classical Greek literature remains relevant. We also discuss the latest news in the life sciences, including the abrupt resignation of the celebrity scientist who led Stanford University and the implications of tornado damage at a Pfizer plant.

en

388 results

Similar Podcasts

TaxTalent.com The Golden Rule Podcast

Adam Golden

TaxTalent.com Podcast

Tony Santiago

Handelsblatt Crime - spannende Streitfälle der deutschen Wirtschaft

Ina Karabasz, Solveig Gode, Sönke Iwersen

Deffner und Zschäpitz – Der Wirtschafts-Talk von WELT

WELT

Black Box - La scatola nera della finanza

Guido Brera e Gian Luca Comandini -...